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ABSTRACT
Objective: Numerous studies demonstrate the efficacy of antibiotic prophylaxis for reducing post-
cesarean section infectious morbidity. The duration of therapy, however, remains controversial.
Cost containment measures and the ease of single dosing have led to the introduction of "extended"
half-life agents for cesarean-section chemoprophylaxis. We tested the hypothesis that there was no
difference in efficacy between a single dose of a short half-life agent (cefoxitin) and a longer half-life
agent (cefotetan).
Methods:A prospective, double-blind trial of375 non-elective cesarean-section cases was carried
out. Study antibiotics (2 g) were administered intravenously (IV) at cord clamping only.
Results: Demographic and clinical variables between the 2 study groups were similar. No signifi-
cant differences were noted in major or minor morbidity or in infectious morbidities for patients
receiving the 2 prophylactic regimens. The occurrence of postoperative endometritis was likewise
similar for the subjects receiving cefoxitin (10%) and cefotetan (15%). When cases whose surgery
lasted >60 min were evaluated separately, no differences in outcomes between the 2 groups were
identified.
Conclusions: These findings confirm our hypothesis that the half-life difference between these 2
agents does not impact on single-dose prophylactic efficacy in cesarean section.
(C) 1994 Wiley-Liss, Inc.
KEY WORDS
Prophylaxis, antibiotics, infectious morbidity
umerous studies have demonstrated the effi-
cacy ofantibiotic prophylaxis in reducing post-
cesarean section infectious morbidity. Controversy
regarding the duration of therapy and cost contain-
ment measures have led to the introduction of "ex-
tended" half-life (tl/2) agents for single-dose use.
Since, in order to be effective, a prophylactic agent
only needs to be present at the time of bacterial
contamination,
2 we tested the hypothesis that there
was no difference in efficacy between a short half-
life agent (cefoxitin: l/2 41-59 min) and a longer-
life agent (cefotetan: t/2 180-276 min). These 2
agents have a similar antibacterial spectrum and are
both recommended to reduce infectious morbidity
after cesarean section. 3’4
SUBJECTS AND METHODS
A prospective trial was conducted from May 1987
through April 1989 at the University of Texas
Medical School at Houston and the University of
Colorado Health Sciences Center in Denver in-
volving 375 subjects undergoing non-elective ce-
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sarean section. This project was approved by each
institution’s investigational review board, and writ-
ten consent was obtained from each subject at entry
in the study.
Patients who underwent cesarean section with at
least major risk factor for developing postopera-
tive infectious morbidity were entered to the study.
The risk factors considered for entry were labor,
membrane rupture, >3 pelvic examinations, and
internal-pressure-transducer monitoring. Patients
were also included in the study if, at the discretion
of the principal investigator, a minor risk factor
(such as obesity, anemia, or intraoperative contam-
ination) mandated antibiotic prophylaxis.
Patients were excluded from the study if they
met any of the following criteria: known hypersen-
sitivity to cephamycins or penicillins; active infec-
tion or fever at the time of cesarean section; sys-
temic antibiotics within 48 h ofsurgery; and history
of renal or hepatic impairment. This study was a
randomized, double-blind comparison of a 2-g sin-
gle intravenous (IV) dose of cefoxitin and a 2-g
single IV dose of cefotetan administered at the time
that the umbilical cord was clamped. Prior to en-
tering the study, patients gave complete histories
and underwent physical examinations. A complete
blood count (CBC), prothrombin time, rapid
plasma reagin test (RPR), and routine urinalysis
were done. An oral or rectal temperature was re-
corded. At the time of cesarean section, incision
and closure times of the abdomen were recorded
and pretherapy aerobic and anaerobic cultures of
the hysterotomy site were collected. Culture and
sensitivity procedures were run in accordance to
NCCLS guidelines.
After surgery, temperature and other vital signs
were taken at least every 4 h until discharge from
the hospital. In the event of an oral temperature
>38C on 2 occasions at least 4 h apart within any
24-h period, excluding the first postoperative day,
the following procedures were generally carried out
to better characterize this febrile morbidity: physi-
cal examination to localize the potential source of
fever; chest X-ray if pulmonary pathology was sus-
pected; urinalysis followed by urine culture if sug-
gestive of infection; and CBC with differential.
Additional antibiotic therapy was initiated after the
above diagnostic studies were completed if deemed
necessary by the attending physician.
Judgments of prophylactic efficacy were made
by the investigator after the completion ofthe study-
drug therapy prior to unblinding of the study. An
assessment of the efficacy was based on the occur-
rence of major or minor postoperative morbidity.
Major morbidity was defined by the occurrence of
or more of the following: generalized sepsis (tem-
perature >38.8C with or without bacteremia);
endometritis (elevated temperature, abnormally ten-
der uterus, foul-smelling lochia, and absence of
other significant pathology); wound infection with
dehiscence or requirement for secondary closure;
pelvic abscess; pelvic cellulitis; or pelvic throm-
bophlebitis. Minor morbidity was defined by the
occurrence of or more of the following: mild-to-
moderate wound infection as defined by purulent
drainage from the suture site and cellulitis of the
wound; urinary-tract infection; postoperative respi-
ratory infection; patient requiring antibiotics; an-
tipyretics with or without proven infection; febrile
morbidity as previously defined without identified
etiology.
All patients were evaluated for safety. Clinical
adverse experiences were described and recorded
by the investigator, who determined the duration,
seriousness, severity, and drug relationship as well
as the eventual outcome of each adverse experience.
Tolerability to the study drug was also addressed.
The chi-squared or Fisher exact test was used to
compare the 2 treatment groups with respect to
patient characteristics, prophylactic success, and in-
cidence of clinical or laboratory adverse experi-
ences. A t-test was used to compare mean ages,
gravidity, parity, duration of surgery, duration of
postoperative hospitalization, duration of ruptured
membranes, duration of labor, and number ofvag-
inal examinations. All tests were 2-tailed and were
done at the 5% significance level.
RESULTS
A total of 375 subjects undergoing cesarean section
were enrolled in this study, 189 of whom were
treated with a single 2-g IV dose of cefoxitin and
186 ofwhom were treated with a single 2-g IV dose
of cefotetan. Three hundred thirty-seven patients
were evaluable for efficacy: 169 in the cefoxitin
group and 168 in the cefotetan group. The patient
characteristics are summarized in Table 1. The
majority of patients (68%) underwent a primary
cesarean section. On average, the surgical proce-
dure lasted for <1 h (54 min). The median dura-
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TABLE I. Demographic and clinical variables of
study groups
a
Cefoxitin Cefotetan
(N= 189) (N= 186)
Age (years) 25.5 -+ 5.7 25.4 _
5.7
Race
Caucasian 83 75
Black 56 59
Other 50 52
Primary cesarean section (No.) II 9* 137
Gravidity 2.7 -+ 1.8 2.4 -
2.0
Duration of surgery (min) 55.5 -+ 25.9 52.9 +- 19.8
Postoperative hospitalization (days) 4.3 _+ 1.8 4.7 -+ 3.2
Vaginal examinations (No.) 3.7 -+ 2.7** 4.6 -+ 3.2
Median duration of ruptured 7 8
membranes (h)
Median duration of labor (h) 12 12
aData presented as mean --+ standard deviation, absolute numbers, or
median values.
*Significantly lower than cefotetan, P < 0.05.
**Significantly lower than cefotetan, P < 0.01.
tion of labor was 12 h and median duration of
ruptured membranes was 7.5 h prior to undergo-
ing cesarean section. Patients remained in the hos-
pital for approximately 4.5 days after surgery.
There were no significant differences between the
cefoxitin and cefotetan groups with respect to any of
the patient characteristics described except that
fewer patients underwent primary cesarean section
in the cefoxitin group (63%) compared with the
cefotetan group (74%). In addition, the mean num-
ber of vaginal examinations in the cefoxitin group
(3.7) was lower than in the cefotetan group (4.6),
and the mean parity was higher in the cefoxitin
group (1.0) than in the cefotetan group (0.8). These
patient characteristic relationships between the 2
study populations remained unaltered when reana-
lyzed for only those subjects evaluable for efficacy.
The proportion of non-evaluable patients in the
cefoxitin group (11%) was similar to the propor-
tion of non-evaluable patients in the cefotetan group
(10%). A total of 23 patients were entered in the
study with only minor risk factors, 11 into the
cetoxitin arm and 12 into the cefotetan arm.
For the evaluable patients, 87% of the patients in
the cefoxitin group had no postoperative febrile
morbidity compared with 79% of patients in the
cefotetan group. Major morbidity occurred post-
cesarean section in 11% of evaluable patients who
received intraoperative cefoxitin and in 16% of
TABLE 2. Types of major and minor morbidities
a
Cefoxitin Cefotetan
(N 169) (N 168)
Major morbidities
Endometritis 17 (10.1%) 25 (14.9%)
Wound infection/dehiscence (0.6%) 5 (3.0%)
Generalized sepsis 2 (I.2%) (0.6%)
Pelvic thrombophlebitis 2 (I.2%) (0.6%)
Pelvic abscess 0 (0.0%) (0.6%)
Other 0 (0.0%) (0.6%)
Minor morbidities
Fever 2 (I.2%) 4 (2.4%)
Wound infection (0.6%) 5 (3.0%)
Uninary-tract infection (0.6%) 3 (I.8%)
Other 2 (I.2%) 2 (I.2%)
aFor patients with multiple major and/or minor morbidities, each event is
counted separately.
evaluable patients who received intraoperative ce-
fotetan. Included in the patients with major mor-
bidity were patient in the cefoxitin and 5 patients
in the cefotetan groups who had both major and
minor morbidities. Four patients in the cefoxitin
group and 6 patients in the cefotetan group had
multiple major morbidities. Four (2.0%) of the
evaluable patients who received cefoxitin and 8
(5.0%) of those who received cefotetan developed
minor morbidity only. One patient in the cefoxitin
graup and 2 patients in the cefotetan group had
multiple minor morbidities. These differences in
both major and minor morbidity between the 2
treatment groups were not statistically significant
(P 0.14).
Prophylactic efficacy was further examined by
subpopulations of the evaluable subjects. There
were no differences in morbidity between study
groups for those patients having surgeries lasting
>60 min, repeat cesarean section, internal-trans-
ducer monitoring, labor >18 h, or >3 vaginal
examinations. However, a significant reduction in
morbidity was noted in the cefoxitin group com-
pared with the cefotetan group for those subjects
having surgeries lasting <60 rain (P 0.01), pri-
mary cesarean section (P 0.03), and having rup-
tured membranes <7 h duration (P 0.01).
Table 2 lists the established etiologies for the
major and minor morbidities identified in the eval-
uable patients in both study groups. An analysis of
the data in Table 2, excluding fever alone and
unclassified morbidities, demonstrated no differ-
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TABLE 3. Pretherapy microbiologic results
of endometrial cultures taken at the time
of cesarean section
Cefoxitin Cefotetan
(N 41) (N 40)
Staphylcoccus sp. 14 17
Streptococcus, group B 10 8
Gardnerella vaginalis 9 7
Gamma streptococcus 6 3
Lactobacillus sp. 5 5
Propionibacterium sp. 5 5
Bacteroides sp. 3 2
Alpha streptococcus 2 3
Anaerobic gram-positive rod 2
Peptostreptococcus sp. 2
Streptococcus, group D
Pseudomonas sp.
Corynebacterium sp. 4
Propiogranulosum sp.
Micrococcus sp.
Yeast
Enterococcus sp.
Proteus mirabilis
Escherichia coli
Bacteroides fragilis
Bacillus cereus
ence between the 2 study populations for infectious
morbidity. The clinical diagnosis of endometritis
accounted for 10% and 15% of the total evaluable
patients in the cefoxitin and cefotetan groups, re-
spectively. The differences noted in endometritis
were not significantly different between prophylac-
tic therapy groups.
Pretherapy intraoperative endometrial cultures
were available for 94 and 86 subjects in the cefox-
itin and cefotetan groups, respectively. Of these,
53 (56%) and 46 (50%) were negative for any
identifiable organisms. Table 3 demonstrates the
results ofthe culture-positive subjects for each study
group. Averages of 1.5 and 1.6 organisms/culture
were identified, respectively.
When major morbidity was clinically suspected,
postoperative endometrial cultures were obtained
by transcervical aspiration. Organisms were iso-
lated in 10/18 evaluable patients in the cefoxitin
group and 16/28 patients in the cefotetan group.
Two and 3 patients in each group, respectively,
were culture negative. Endometrial culture results
were not available from 6 and 9 subjects, respec-
tively, diagnosed to have major morbidity in each
study group. Table 4 presents the microbiologic
TABLE 4. Endometrial isolates from patients with
major morbidity
Cefoxitin Cefotetan
Pathogen class (N 10) (N 16)
Gram-positive aerobic cocci
Staphylococcus aureus 0 2
Staphylococcus epidermidis
Staphylococcus, coagulase negative
Streptococci (group B) 0 4
Streptococci (group D 5 7
enterococci)
Streptococci (group D 0
non-enterococci)
Gram-negative aerobic rods
Escherichia coli 3 0
Hemophilus influenzae 0
Pseudomonas aeruginosa 0
Gram-positive anaerobic rods
Lactobacillus 0
Gram-positive anaerobic cocci
Peptostreptococcus anaerobius 0 2
Gram-negative anaerobic rods
Bacteroides bivius 4 2
Bacteroides capillosus 0
Bacteroides melaninogenicus 2 0
Bacteroides oralis 0
Gardnerella vaginalis 0
Gram-negative bacteria
Gram-negative rods 0
aSome patients had >1 pathogen isolated. Endometritis accounted for
>90% of all major morbidity.
results of patients with major morbidity who were
culture positive. Endometritis accounted for >90%
of major morbidity (17/18 patients in the cefoxitin
group and 25/27 patients in the cefotetan group).
Polymicrobial infections were common with 2.9
and 2.7 organisms identified per culture, respec-
tively.
All 375 patients enrolled in this study were in-
cluded in the analysis of safety. Eight patients had a
clinical adverse experience, 3 patients in the cefox-
itin group and 5 patients in the cefotetan group.
None of the patients in either treatment group had a
serious clinical adverse experience. All clinical ad-
verse experiences were judged to probably not, or
definitely not, be related to the study drugs. The
proportions of patients with clinical adverse experi-
ences were similar in the cefoxitin and cefotetan
groups. No patients were discontinued from the
study due to a clinical adverse experience. Two
patients in the cefoxitin group and 3 patients in the
cefotetan group had a laboratory adverse experi-
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ence. These differences were not statistically signif-
icant. The study drug was well tolerated in all
patients in both treatment groups.
DISCUSSION
Cesarean section is one of the most common opera-
tive procedures performed on an obstetrics and gy-
necology service.
5 In patients undergoing cesarean
section with recognized risk factors, infectious mor-
bidity in the form of postpartum endometritis,
would infection, or urinary-tract infection is rela-
tively frequent.
1,6,7 Numerous studies have docu-
mented the efficacy of a variety of regimens for
antibiotic prophylaxis to reduce postoperative in-
fectious morbidity. Although this general approach
has led to significant reductions in hospital-based
costs, further attempts at cost containment have
prompted the recommendation to use less expensive
(and less broad-spectrum) antimicrobial agents and
to reduce the number of perioperative antibiotic
doses.
9 A number of investigators have supported
these latter recommendations, although uniform
agreement does not exist due to concerns regarding
confounding variables such as differences in patient
population demographics.
1 Regardless, the data
seem clear that absolute polymicrobial susceptibil-
ity to a given prophylactic agent is not necessary to
demonstrate a reduction in infectious morbidity fol-
lowing cesarean section. Additionally, recent infor-
mation has suggested that incipient but established
infection (as opposed to bacterial colonization) at
the time ofsurgery is a critical mechanism by which
patients fail prophylaxis.
11
By definition, antimicrobial prophylaxis is in-
tended to reduce bacterial colonization and contam-
ination at the time of surgery so that the host’s
endogenous immune responses can overcome the
threat of infection.
2 Therefore, adequate tissue con-
centrations of a given prophylactic agent empiri-
cally should be present during the time of cesarean
section. This also implies that relatively short half-
life agents should be efficacious since this operative
procedure uncommonly exceeds h. Again, nu-
merous studies examining such agents confirm this
fact and contradict those advocating that only ex-
tended half-life agents should be used for single-
dose prophylaxis.
1,6,7,9 Indeed, the data from our
study, which represents one of the largest studies to
compare 2 agents with a similar microbial spec-
trum, yet with different half-lives, support this
conclusion. Of interest, similarities in efficacy held
true even for those cases in which the time of sur-
gery was extended. Although cefoxitin was found to
be statistically more efficacious than cefotetan in
several ofour subpopulation analyses (surgery <60
min, primary cesarean section, and ruptured mem-
branes <7 h), the clinical significance of these
findings is unclear, especially since others have
reported no differences between these 2 prophylac-
tic agents.
One should keep in mind the fact that hospital-
related costs are most influenced by hospitalization
days, intensive-care admission, and the need for
additional operative procedures.
13 Therefore, anti-
microbial efficacy should be the primary consider-
ation in choosing a prophylactic agent. Given the
general acceptance of single-dose prophylaxis, cost
determinations should be based on gram-for-gram
comparisons, not on tangential issues such as dosing
intervals or nursing-administration time require-
ments; these are more of concern when evaluating
therapeutic antibiotic regimes. Lastly, ongoing
monitoring for clinical failure rates, resistance pat-
terns, side effects, and pharmacy cost fluctuations
should be undertaken at each individual institution
to assure cost-effective quality care.
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